Notice of Intent LIFETECHNOLOGIES INC.docx
DOCX document 76 KB Posted
- Solicitation number
- 75N98026Q00677
About this file
This is a Notice of Intent from Life Technologies Inc. regarding a pre-solicitation opportunity for whole exome analysis services for the National Institute on Alcohol Abuse and Alcoholism (NIAAA) Clinical Center.
The NIAAA Clinical Center seeks to continue whole exome sequencing analysis of its patient cohort to identify sequence variant differences and treatment response changes in alcohol-related disorders. The analysis will process over 2,000 patient samples using the AmpliSeq Exome enrichment system and ION sequencing platform, the same platforms used for previously analyzed samples. Platform consistency is critical to maintain analytical integrity, as each sequencing platform produces unique error patterns that could compromise data comparability across samples analyzed at different time periods. The solicitation is being issued by the Department of Health and Human Services National Institutes of Health Office of Logistics and Acquisition Operations. Life Technologies Inc.'s notice of intent indicates the company's interest in competing for this requirement, which involves providing genomic sequencing and analysis services utilizing specific, previously-established technology platforms.
View the file
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Hospital and Laboratory Support Division Office of Logistics and Operations (OLAO) Office of Acquisition and Logistics Management (OALM)
Title: Whole Exome Analysis of NIAAA Clinical Center PATIENTS
Presolicitation
98026Synopsis No. 75N98026Q00677 75N98026Q0067775N98026Q0067175N98026Q0067175N98026Q00671 javascript:__doPostBack('ctl00$ctl00$body$homebody$RecentDocuments$C$RecentDocumentsControl$RecentDocumentResults$ctl00$DocumentNumberLink',''):75N98026Q00671: 75N98026Q00671: 75N98026Q00671
SYNOPSIS
General Information
| Document Type: |
| Presolicitation |
| Synopsis Number: |
| 75N98026Q00677 |
| Posted Date: |
| JUNE 22ND 2026 |
| Original Response Date: |
| JULY 2ND 2026 |
| Current Response Date: |
| JULY 2ND 2026 |
| Set Aside: |
| N/A |
| NAICS Code: |
| 325414 |
Contracting Office Address
National Institutes of Health (NIH), Office of the Director (OD) Office of Logistics and Operations (OLAO) Office of Acquisition and Logistics Management (OALM) Hospital and Laboratory Support Division 6701 Rockledge Drive Bethesda, MD 20817
Description
INTRODUCTION
THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).
The National Institutes of Health (NIH) intends to negotiate and award a contract without providing for full and open competition (Including brand-name) to:
LIFE TECHNOLOGIES CORPORATION
3175 Staley RD Grand Island, New York 14072-2028 United States
NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE
The intended procurement is classified under NAICS code 325414 with a Size Standard $34M.
REGULATORY AUTHORITY
The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2005-99-1, July 16, 2018. This acquisition is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures at an amount not exceeding the simplified acquisition threshold ($350,000).
STATUTORY AUTHORITY
This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source and is not expected to exceed the simplified acquisition threshold. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.
GENERAL INFORMATION
1) Title: Whole Exome Analysis of NIAAA Clinical Center Patients
2) Background Information: The NIAAA Clinical Center patient cohort has been analyzed patients for sequence variant differences, and changes in response to treatment over the course of many years as part of an effort to identify underlying causes of alcohol related disorders. Analysis has previously been performed on over 2000 patients using the AmpliSeq Exome enrichment system and sequenced on the ION sequencing platform because it provides the capability of cost-effective high throughput whole-exome genome-wide analysis. The use of a single enrichment and sequencing platform with consistent information content is essential for analysis of samples screened at different times and it is therefore imperative for analytical integrity that all samples in the study are processed on the same sequencing platform, as each platform has a unique pattern of error
CLOSING STATEMENT
This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include a technical proposal, a cost-price proposal, the period of performance, the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.
A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.
All responses must be received by JULY 2ND 2026, at 9:00 AM Eastern time and must reference solicitation number 75N98026Q00677 Responses may be submitted electronically to Mr. VISHNUVAJJAL HANUMANTH RAO , VISHNUH@MAIL.NIH.GOV VISHNUH@MAIL.NIH.GOV Fax responses will not be accepted.
"All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.”
image1.png
File details come from the government source that posted it. Updated .